瑞舒伐他汀协同治疗对急性冠脉综合征患者血清炎性因子水平的影响∗

摘要

Objective:To observe the levels of high-sensitive C-reaction protein (hs-CRP),tumor necrosis factor-α(TNF-α)and interleukin-18 (IL-18)in the acute coronary syndrome (ACS)patients before and after rosuv-astatin calcium treatment.Method:The 140 cases of hospitalized patients with ACS were divided into three groups, unstable angina pectoris (UAP group,n=62),non-ST-elevation acute myocardial infarction (NSTEMI group,n=35)and ST-elevation acute myocardial infarction (STEMI group,n=43).Meanwhile,healthy people treated as the control group (healthy control group,n=50).All ACS patients admitted to routine therapy combined with rosuvas-tatin treatment for two weeks.The levels of hs-CRP,TNF-αand IL-1 8 were detected and analysed before and after treatment using immunoassay nephelometry and enzyme-linked immunosorbent assays.Results:After 2 weeks treat-ment,the levels of hs-CRP,TNF-αand IL-1 8 of ACS groups decreased significantly compared with before treatment (P<0.01)and the levels of them in each group before treatment was higher than the healthy control group (P<0. 01).There were no significant difference of inflammatory factors level among the four groups after treatment (P>0.05).Conclusion:Rosuvastatin calcium may obviously reduce the serum inflammatory levels to treat ACS.%目的：：观察急性冠脉综合征(ACS)患者应用瑞舒伐他汀协同治疗前后血清超敏 C 反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-18(IL-18)水平变化。方法：住院 ACS患者140例,分为不稳定型心绞痛组(UAP组,n=62)、急性非 ST 段抬高型心肌梗死组(NSTEMI 组,n=35)及急性 ST 段抬高型心肌梗死组(STEMI组,n=43)；选择同期体检健康者作为对照组(健康对照组,n=50)。所有 ACS患者从入院当日开始行常规治疗联合瑞舒伐他汀治疗2周。分别采用免疫比浊法和酶联免疫吸附法检测各组 ACS治疗前后血清 hs-CRP、TNF-α及 IL-18水平,比较各组各指标水平差异及治疗前后变化。结果：治疗前 ACS各组血清 hs-CRP、TNF-α及IL-18水平均高于健康对照组(P<0.01)；治疗2周后,ACS各组三项指标均较治疗前明显降低(P均<0.01),且与健康对照组比较差异均无统计学意义(P>0.05)。结论：瑞舒伐他汀可能通过明显降低血清炎性因子治疗ACS。